Related Experiment Video

Updated: Jul 20, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Effect of hypoproteinemia on treatment outcome in children with acute lymphoblastic leukemia

Atta-ur-rehman Khan1, Moeen-ul-haq Sheikh, Kiran Intekhab

  • 1Department of Ancillary Health Services, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. rehmanatta71@skm.org.pk

Journal of Ayub Medical College, Abbottabad : JAMC
|September 19, 2006
PubMed

Insights

Malnutrition significantly worsens treatment outcomes in children with acute lymphoblastic leukemia. Malnourished children experienced higher mortality and lower treatment completion rates compared to well-nourished children.

Area of Science:

  • Pediatric Oncology
  • Clinical Nutrition
  • Hematology

Background:

  • Hospitalized patients frequently suffer from malnutrition, increasing morbidity, mortality, and reducing treatment efficacy.
  • Early identification and management of malnutrition are crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the impact of hypoproteinemia-induced malnutrition on treatment outcomes in pediatric acute lymphoblastic leukemia (ALL).

Main Methods:

  • A prospective study included 163 children under 14 with ALL (L1/L2 FAB morphology) treated with the FBM protocol.
  • Patients were categorized as Well-Nourished (Group I) or Mal-nourished (Group II) using Waterlow classification.
  • Outcomes assessed included treatment completion, relapse rates, and mortality.

Main Results:

  • Mal-nourished children (Group II) had significantly lower treatment completion (30.39%) and higher mortality (61.76%) compared to well-nourished children (Group I: 81.96% completion, 9.8% mortality).
  • Relapse rates were similar between groups, but overall survival was markedly reduced in the malnourished cohort.
  • The overall mortality in the malnourished group was 63 (38.65%) compared to 6 (3.68%) in the well-nourished group.

Conclusions:

  • Hypoproteinemia and malnutrition negatively impact treatment outcomes in children with acute lymphoblastic leukemia.
  • Addressing nutritional status is critical for improving survival rates in pediatric ALL patients.
Abstract

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...